Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine

World News: . []

BOTHELL Wash June 29 2018 GLOBE NEWSWIRE -- Alder BioPharmaceuticals Inc NASDAQALDR a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced n ew one-...

More news and information about Alder Biopharmaceuticals, Inc.

Published By:

Globe Newswire: 13:30 GMT Friday 29th June 2018

Published: .

Search for other references to "alder" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us